GlassScriptPhysician profile
Sierra Izzo
NPI 1881333722
$1,885.10
in general payments reported to CMS, 2019-2025
18 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $759 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $394.86 | 2024-2025 | Entyvio, Eohilia |
| Abbvie INC. | $301.36 | 2024-2025 | |
| Janssen Biotech, INC. | $237.04 | 2024-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $210.32 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $132.15 | 2024 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $94.58 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $91.51 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $75.46 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.40 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $68.05 | 2025 | |
| Ardelyx, INC. | $44.32 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $41.01 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $29.05 | 2024-2025 | |
| Genzyme Corporation | $24.79 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.61 | 2025 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.72 | 2025 | Terlivaz |
| Celgene Corporation | $14.93 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $13.94 | 2024 | Dificid, Zinplava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sierra Izzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.